Reduced IL-33 plasma levels in multiple myeloma patients are associated with more advanced stage of disease

British Journal of Haematology

Volumn 160, Issue 5, 2013, Pages 709-710

  Musolino, Caterina ^a   Allegra, Alessandro ^a   Profita, Mirella ^b   Alonci, Andrea ^a   Saitta, Salvatore ^c   Russo, Sabina ^a   Bonanno, Anna ^b   Innao, Vanessa ^a   Gangemi, Sebastiano ^b,c  

^a UNIVERSITY OF MESSINA   (Italy)

^b Division of Allergy and Clinical Immunology   (Italy)

^c CNR Consiglio Nazionale delle Ricerche   (Italy)

Author keywords

Cytokines; Interleukin 33; MGUS; Microenvinroment; Multiple myeloma; Th2

Indexed keywords

BETA 2 MICROGLOBULIN; HEMOGLOBIN; IMMUNOGLOBULIN A; IMMUNOGLOBULIN G; INTERLEUKIN 33;

ADULT; AGED; BONE ATROPHY; CANCER STAGING; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE SEVERITY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HEMOGLOBIN BLOOD LEVEL; HUMAN; KIDNEY FAILURE; LETTER; MALE; MONOCLONAL IMMUNOGLOBULINEMIA; MULTIPLE MYELOMA; PATHOLOGIC FRACTURE; PLASMACYTOSIS; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL;

AGED; FEMALE; HUMANS; INTERLEUKINS; KIDNEY FAILURE, CHRONIC; MALE; MIDDLE AGED; MONOCLONAL GAMMOPATHY OF UNDETERMINED SIGNIFICANCE; MULTIPLE MYELOMA; MYELOMA PROTEINS; NEOPLASM STAGING; OSTEOLYSIS;

EID: 84873989030     PISSN: 00071048     EISSN: 13652141     Source Type: Journal    
DOI: 10.1111/bjh.12146     Document Type: Letter

References (9)

1. Cevikbas, F. & Steinhoff, M. (2012) IL-33: a novel danger signal system in atopic dermatitis. Journal of Investigative Dermatology, 132, 1326-1329.
2. Jöhrer, K., Hofbauer, S.W., Zelle-Rieser, C., Greil, R. & Hartmann, T.N. (2012) Chemokine-dependent B cell-T cell interactions in chronic lymphocytic leukemia and multiple myeloma - targets for therapeutic intervention? Expert opinion on biological therapy, 12, 425-441.
3. Joshi, A.D., Oak, S.R., Hartigan, A.J., Finn, W.G., Kunkel, S.L., Duffy, K.E., Das, A. & Hogaboam, C.M. (2010) Interleukin-33 contributes to both M1 and M2 chemokine marker expression in human macrophages. BioMed Central immunology, 11, 52-60.
4. Minges Wols, H.A., Underhill, G.H., Kansas, G.S. & Witte, P.L. (2002) The role of bone marrow-derived stromal cells in the maintenance of plasma cell longevity. Journal of Immunology, 169, 4213-4221.
5. Osterborg, A., Yi, Q., Bergenbrant, S., Holm, G., Lefvert, A.K. & Mellstedt, H. (1995) Idiotype-specific T cells in multiple myeloma stage I: an evaluation by four different functional tests. British Journal of Haematology, 89, 110-116.
6. Prabhala, R.H., Blacks, P., Bae, J.E., Tassone, P., Shammas, M.A., Allam, C.K., Daley, J.F., Chauhan, D., Blanchard, E., Thatte, H.S., Anderson, K.C. & Munshi, N.C. (2006) Dysfunctional T regulatory cells in multiple myeloma. Blood, 107, 301-304.
7. Pratt, G., Goodyear, O. & Moss, P. (2007) Immunodeficiency and immunotherapy in multiple myeloma. British Journal of Haematology, 138, 563-579.
8. Wang, S., Hong, S., Wezeman, M., Qian, J., Yang, J. & Yi, Q. (2007) Dendritic cell vaccine but not idiotype-KLH protein vaccine primes therapeutic tumor-specific immunity against multiple myeloma. Frontiers in Bioscience, 12, 3566-3575.
9. Yi, Q., Osterborg, A., Bergenbrant, S., Mellstedt, H., Holm, G. & Lefvert, A.K. (1995) Idiotype-reactive T-cell subsets and tumor load in monoclonal ammopathies. Blood, 86, 3043-3049.